advertisement
Pham K 12
Showing records 1 to 12 | Display all abstracts from Pham K128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
Pham K
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Zhu Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
Pham K; Jin F; Jin F
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Moksha L
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
Lee R
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Salowe R; Vrathasha V
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
Di Rosa I; Salowe R
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Pham K; Pham K
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
Ying GS
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Aibo MI; Aibo MI; Lee R
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
128459 Association between Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Use and Primary Open-Angle Glaucoma Risk in All of Us
O'Brien JM
Ophthalmology 2025; 132: 1212-1216
127256 Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds
Halimitabrizi M; Di Rosa I; O'Brien JM
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2025; 190: 118319
